Astellas has menopause accelerated approval ambition thwarted by FDA at last minute

Astellas’ bid to bring menopause drug candidate fezolinetant to market has hit a last-minute snag. Just days before the approval decision date, the FDA has extended the review by three months to give it more time to complete its assessment.